Overview

Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome

Status:
Completed
Trial end date:
2018-07-12
Target enrollment:
Participant gender:
Summary
This trial is conducted in Asia. The aim of the trial is to investigate the long-term efficacy and safety of two doses of NN-220 (somatropin) in short stature due to Noonan syndrome.
Phase:
Phase 3
Details
Lead Sponsor:
Novo Nordisk A/S